PriceTargets.com logo

Innovate Biopharmaceuticals - INNT Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 04/19/2024 01:00 AM ET
+0 (0.00%)
Get New Innovate Biopharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for INNT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for INNT

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for Innovate Biopharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for INNT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Innovate Biopharmaceuticals. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/1/2019HC WainwrightLower TargetBuy$35.00 ➝ $10.00High
(Data available from 4/19/2019 forward)

News Sentiment Rating

0.39 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/22/2023
  • 2 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2023
  • 1 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2023
  • 3 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2023
  • 2 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/20/2024
  • 4 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/19/2024
  • 5 very positive mentions
  • 24 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
3/20/2024
  • 3 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
4/19/2024

Current Sentiment

  • 3 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Innovate Biopharmaceuticals logo
Innovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH). In addition, the company holds rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase III clinical trial. The company has a research collaboration with Massachusetts General Hospital for the treatment of ASH. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.97
Low: $0.56
High: $1.42

52 Week Range

Now: N/A

Volume

155 shs

Average Volume

525,982 shs

Market Capitalization

$8 thousand

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Innovate Biopharmaceuticals?

The following Wall Street research analysts have issued reports on Innovate Biopharmaceuticals in the last year:
View the latest analyst ratings for INNT.

What is the current price target for Innovate Biopharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Innovate Biopharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Innovate Biopharmaceuticals in the next year.
View the latest price targets for INNT.

What is the current consensus analyst rating for Innovate Biopharmaceuticals?

Innovate Biopharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for INNT.

What other companies compete with Innovate Biopharmaceuticals?

Other companies that are similar to Innovate Biopharmaceuticals include NVN Liquidation, Genocea Biosciences, Kaleido Biosciences, HTG Molecular Diagnostics and Viveve Medical. Learn More about companies similar to Innovate Biopharmaceuticals.

How do I contact Innovate Biopharmaceuticals' investor relations team?

Innovate Biopharmaceuticals' physical mailing address is 8480 HONEYCUTT ROAD SUITE 120, RALEIGH NC, 27615. The company's listed phone number is 919-275-1933 and its investor relations email address is [email protected]. The official website for Innovate Biopharmaceuticals is www.innovatebiopharma.com. Learn More about contacing Innovate Biopharmaceuticals investor relations.